The effect of Myrtoid and 2% diltiazem with placebo in treatment of complications of chronic anal fissure patients

Clinical trial Study of the effect of Myrtoid and 2% diltiazem with placebo in treatment of complications of chronic anal fissure patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160914029818N3

Enrollment

Registered

2018-01-27

Start date

2017-04-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic anal fissure. Chronic anal fissure

Interventions

Intervention 1: Intervention group: Myrtoid. Intervention 2: Intervention group: 2% diltiazem. Intervention 3: Control group: Suppository placepo.

Treatment - Drugs

Placebo

Intervention group: Myrtoid

Intervention group: 2% diltiazem

Control group: Suppository placepo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having at least 2 months of chronic anal fissure

Exclusion criteria

Exclusion criteria: Patients with Crohn's disease Patients with colon cancer Patients with diabetes History of anal surgery

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Two weeks after traetment. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
Itching. Timepoint: Two weeks after treatment. Method of measurement: Questionnaires with Likert scale ( low, medium and high).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Manoochehry

Bagheiat-allah University of Medical Sciences

shahram.manoochehry@yahoo.com+98 21 8805 3766

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026